Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Feb. 10, 2012 - PRLog -- GlobalData’s analysis shows that the global Tourette Syndrome (TS) therapeutics market was valued at
$170.8m in 2011, and is forecast to decline at a Compound Annual Growth Rate (CAGR) of -3.3% to $130m by 2019. The current therapeutics market is served by approved drugs such as haloperidol and pimozide and off-label drugs such as Abilify (aripiprazole), risperidone, clonidine and tetrabenazine. Unlike the forecast period, the historic period saw growth at a CAGR of 0.2%, from $168.8m in 2006 to $170.8m in 2011. This low growth can be attributed to the patent expiry of the off-label drug risperidone in 2007. Despite the increasing diseased population and rising treatment rates, the TS therapeutics market is expected to decline during the forecast period. This is primarily attributed to the patent expiry of the highly-priced off-label drug Abilify in 2014. There are no pipeline products which are expected to significantly impact the market during the forecast period. Abilify (OPC-14597) is in Phase III in the US and at the New Drug Application (NDA) filing stage in Asia.

The TS therapeutics market has two only approved drugs: haloperidol and pimozide. The other drugs used for the treatment of TS are used off-label, namely risperidone, clonidine and Abilify. Importantly, the approved drugs have inadequate levels of safety and efficacy, meaning that off-label drugs dominate treatment for TS. It has a low treatment seeking rate, as symptoms tend to disappear gradually with increasing age. Non-pharmacological treatment options such as behavioral therapy are also used, particularly for treating affected children and adolescen.

The TS therapeutics pipeline has four molecules in development. Abilify is an off-label drug and is in the late stage of the pipeline. There are two products in Phase II and one in Phase I. This weak pipeline is not expected to intensify the competition in the market, currently centered on off-label products risperidone, clonidine and Abilify. This trend is likely to continue throughout the forecast period.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData, the industry analysis specialist, has released its new report, “Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Tourette Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Tourette Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Tourette Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Tour...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.